Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
Immunopheresis™️ therapy holds great promise for avoiding serious drawbacks of existing pharmaceuticals and improving patients’ quality of life SAN DIEGO, March 23, 2021 – Immunicom, Inc., a global biotechnology company pioneering novel “subtractive” immunotherapies, today announced that the ImmunopheresisTM LW-02 blood-filtering column, its leading immuno-oncology product with FDA Breakthrough Device status, has received regulatory clearance (CE Mark … Continued